COVID-19 leading to shortage of orphan drugs in Russia

5 May 2020

The ongoing spread of COVID-19 in Russia is leading to shortages of drugs against orphan diseases in the local market, according to recent statements by some senior state officials of the Russian Ministry of Health and local analysts, reports The Pharma Letter’s local correspondent.

Since the beginning of pandemic, a significant number of drugs that are used for the treatment of rare diseases have started to be recommended by the Russian Ministry of Health for the possible treatment of COVID-19. That has led to growth of the demand for them from various local hospitals and medical institutions, which in recent weeks have been re-oriented on the treatment of patients with COVID-19.

That, in turn, has resulted in the reduction of supplies of these drugs to the patients suffering from rare diseases, while the biggest problems currently observed is in the case of patients with rheumatoid arthritis and systemic lupus erythematosus (SLE).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK